Heart Disease Clinical Trials in Omaha, NE

46 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS	Phase 3	DalCor Pharmaceuticals	<1 mi
Randomization of Single vs Multiple Arterial Grafts	N/A	Weill Medical College of Cornell University	<1 mi
Assessment of CCM in HF With Higher Ejection Fraction	N/A	Impulse Dynamics	<1 mi
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women	N/A	Weill Medical College of Cornell University	<1 mi
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity	Phase 3	SWOG Cancer Research Network	<1 mi
Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure	N/A	Analog Device, Inc.	<1 mi
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure	N/A	BrioHealth Solutions, Inc.	<1 mi
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2	Phase 3	Mezzion Pharma Co. Ltd	<1 mi
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure	N/A	Abbott Medical Devices	<1 mi
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart	Phase 3	Boehringer Ingelheim	<1 mi
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery	Phase 3	Yale University	<1 mi
Quality of Pediatric Resuscitation in a Multicenter Collaborative	—	Children's Hospital of Philadelphia	<1 mi
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients	Phase 3	Colorado Prevention Center	<1 mi
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin	Phase 3	AstraZeneca	<1 mi
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator	Phase 4	University of Rochester	<1 mi
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease	—	Children's Hospital Medical Center, Cincinnati	<1 mi
PULSED AF Post-Approval Study	—	Medtronic Cardiac Ablation Solutions	<1 mi
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction	Phase 3	Cytokinetics	<1 mi
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products	—	Medtronic	<1 mi
Encore PFO Closure Device - The PerFOrm Trial	N/A	Encore Medical Inc.	<1 mi
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)	Phase 3	Novartis Pharmaceuticals	<1 mi
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)	Phase 2	Tectonic Therapeutic	<1 mi
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)	N/A	XVIVO Perfusion	<1 mi
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation	Phase 3	Novo Nordisk A/S	<1 mi
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)	Phase 2	Merck Sharp & Dohme LLC	<1 mi
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes	Phase 4	VA Office of Research and Development	<1 mi
Product Surveillance Registry	—	Medtronic	<1 mi
Tracking Results of Ablations to Combat AF Registry Generation 2	—	AtriCure, Inc.	<1 mi
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF	Phase 3	Tenax Therapeutics, Inc.	<1 mi
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)	—	Bristol-Myers Squibb	<1 mi
The CONFORM Pivotal Trial	N/A	Conformal Medical, Inc	<1 mi
Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)	N/A	University of Michigan	<1 mi
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)	—	Duke University	<1 mi
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)	Phase 2	Pfizer	50 mi
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention	Phase 4	Duke University	50 mi
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement	N/A	University of British Columbia	50 mi
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)	Phase 3	Anthos Therapeutics, Inc.	50 mi
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure	Phase 3	Boehringer Ingelheim	50 mi
AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM	—	Cordio Medical	50 mi
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events	Phase 3	Amgen	50 mi
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function	Phase 3	AstraZeneca	50 mi
Abbott Vascular Medical Device Registry	—	Abbott Medical Devices	50 mi
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity	Phase 3	Amgen	50 mi
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events	N/A	Cleerly, Inc.	50 mi
PARTNER 3 Trial - Aortic Valve-in-Valve	N/A	Edwards Lifesciences	50 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	Phase 2/3	CSL Behring	50 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.